Raul R Gainetdinov

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8594420/publications.pdf

Version: 2024-02-01

315	35,640	3933	3487
papers	citations	88 h-index	182 g-index

338	338	338	30597
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacological Reviews, 2011, 63, 182-217.	16.0	2,109
2	Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia. Cell, 1999, 98, 427-436.	28.9	1,002
3	Enhanced Morphine Analgesia in Mice Lacking Î²-Arrestin 2. Science, 1999, 286, 2495-2498.	12.6	953
4	Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature, 2011, 476, 224-227.	27.8	941
5	An Akt/Î²-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior. Cell, 2005, 122, 261-273.	28.9	903
6	Plasma membrane monoamine transporters: structure, regulation and function. Nature Reviews Neuroscience, 2003, 4, 13-25.	10.2	846
7	Î¼-Opioid receptor desensitization by Î²-arrestin-2 determines morphine tolerance but not dependence. Nature, 2000, 408, 720-723.	27.8	834
8	Role of Serotonin in the Paradoxical Calming Effect of Psychostimulants on Hyperactivity. Science, 1999, 283, 397-401.	12.6	813
9	DESENSITIZATION OF G PROTEINâ€“COUPLED RECEPTORS AND NEURONAL FUNCTIONS. Annual Review of Neuroscience, 2004, 27, 107-144.	10.7	755
10	Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5099-5104.	7.1	739
11	Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4029-4034.	7.1	623
12	Tryptophan Hydroxylase-2 Controls Brain Serotonin Synthesis. Science, 2004, 305, 217-217.	12.6	591
13	Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter. Journal of Neuroscience, 1998, 18, 1979-1986.	3.6	526
14	The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. British Journal of Pharmacology, 2015, 172, 6024-6109.	5.4	521
15	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
16	Akt/GSK3 Signaling in the Action of Psychotropic Drugs. Annual Review of Pharmacology and Toxicology, 2009, 49, 327-347.	9.4	507
17	The Concise Guide to PHARMACOLOGY 2015/16: G proteinâ€coupled receptors. British Journal of Pharmacology, 2015, 172, 5744-5869.	5.4	507
18	Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1982-1987.	7.1	485

#	Article	IF	Citations
19	Cocaine self-administration in dopamine-transporter knockout mice. Nature Neuroscience, 1998, 1, 132-137.	14.8	463
20	Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8987-8992.	7.1	459
21	Physiological Roles of G Proteinâ€“Coupled Receptor Kinases and Arrestins. Annual Review of Physiology, 2007, 69, 511-534.	13.1	436
22	Mice lacking the norepinephrine transporter are supersensitive to psychostimulants. Nature Neuroscience, 2000, 3, 465-471.	14.8	435
23	Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron, 2005, 45, 11-16.	8.1	420
24	Dopamine receptors â€“ <scp>IUPHAR R</scp>eview 13. British Journal of Pharmacology, 2015, 172, 1-23.	5.4	409
25	The Aktâ€“GSK-3 signaling cascade in the actions of dopamine. Trends in Pharmacological Sciences, 2007, 28, 166-172.	8.7	385
26	Food Reward in the Absence of Taste Receptor Signaling. Neuron, 2008, 57, 930-941.	8.1	377
27	Knockout of the Vesicular Monoamine Transporter 2 Gene Results in Neonatal Death and Supersensitivity to Cocaine and Amphetamine. Neuron, 1997, 19, 1285-1296.	8.1	345
28	Monoamine Transporters: From Genes to Behavior. Annual Review of Pharmacology and Toxicology, 2003, 43, 261-284.	9.4	343
29	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
30	Identification of PSD-95 as a Regulator of Dopamine-Mediated Synaptic and Behavioral Plasticity. Neuron, 2004, 41, 625-638.	8.1	335
31	Role of GSK3Î² in behavioral abnormalities induced by serotonin deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1333-1338.	7.1	331
32	A Î²-arrestin 2 Signaling Complex Mediates Lithium Action on Behavior. Cell, 2008, 132, 125-136.	28.9	326
33	Dopamine transporters and neuronal injury. Trends in Pharmacological Sciences, 1999, 20, 424-429.	8.7	313
34	Antagonism of dopamine D2 receptor/Î²-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13656-13661.	7.1	295
35	TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 8485-8490.	7.1	287
36	Dopamine Transporter Is Required for In Vivo MPTP Neurotoxicity: Evidence from Mice Lacking the Transporter. Journal of Neurochemistry, 1997, 69, 1322-1325.	3.9	286

#	Article	IF	Citations
37	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	5.4	269
38	Dopaminergic Control of Sleepâ€“Wake States. Journal of Neuroscience, 2006, 26, 10577-10589.	3.6	262
39	Rapid Alterations in Corticostriatal Ensemble Coordination during Acute Dopamine-Dependent Motor Dysfunction. Neuron, 2006, 52, 359-369.	8.1	261
40	Behavioral and Neurochemical Effects of Wild-Type and Mutated Human Î±-Synuclein in Transgenic Mice. Experimental Neurology, 2002, 175, 35-48.	4.1	255
41	Trace Amines and Their Receptors. Pharmacological Reviews, 2018, 70, 549-620.	16.0	248
42	Regulation of Akt Signaling by D2 and D3 Dopamine Receptors In Vivo. Journal of Neuroscience, 2007, 27, 881-885.	3.6	245
43	Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis1Published on the World Wide Web on 27 January 1998.1. Brain Research Reviews, 1998, 26, 148-153.	9.0	239
44	Role of Dopamine Transporter in Methamphetamine-Induced Neurotoxicity: Evidence from Mice Lacking the Transporter. Journal of Neuroscience, 1998, 18, 4861-4869.	3.6	235
45	Loss of autoreceptor functions in mice lacking the dopamine transporter. Nature Neuroscience, 1999, 2, 649-655.	14.8	235
46	Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 15312-15317.	7.1	235
47	Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice. Journal of Neuroscience, 1999, 19, 2424-2431.	3.6	229
48	The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology, 2015, 172, 5729-5743.	5.4	220
49	Functional hyperdopaminergia in dopamine transporter knock-out mice. Biological Psychiatry, 1999, 46, 303-311.	1.3	216
50	Dopaminergic Supersensitivity in G Protein-Coupled Receptor Kinase 6-Deficient Mice. Neuron, 2003, 38, 291-303.	8.1	208
51	Mice Deficient for the Vesicular Acetylcholine Transporter Are Myasthenic and Have Deficits in Object and Social Recognition. Neuron, 2006, 51, 601-612.	8.1	208
52	Enhanced Rewarding Properties of Morphine, but not Cocaine, in Î²arrestin-2 Knock-Out Mice. Journal of Neuroscience, 2003, 23, 10265-10273.	3.6	203
53	Genetic animal models: focus on schizophrenia. Trends in Neurosciences, 2001, 24, 527-533.	8.6	197
54	Anterior Pituitary Hypoplasia and Dwarfism in Mice Lacking the Dopamine Transporter. Neuron, 1997, 19, 127-138.	8.1	192

#	Article	IF	Citations
55	The Concise Guide to PHARMACOLOGY 2015/16: Transporters. British Journal of Pharmacology, 2015, 172, 6110-6202.	5.4	190
56	Muscarinic Supersensitivity and Impaired Receptor Desensitization in G Proteinâ€“Coupled Receptor Kinase 5â€“Deficient Mice. Neuron, 1999, 24, 1029-1036.	8.1	180
57	Social Context-Dependent Singing-Regulated Dopamine. Journal of Neuroscience, 2006, 26, 9010-9014.	3.6	176
58	The Concise Guide to PHARMACOLOGY 2015/16: Voltageâ€gated ion channels. British Journal of Pharmacology, 2015, 172, 5904-5941.	5.4	176
59	Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor. Molecular Pharmacology, 2011, 80, 416-425.	2.3	175
60	Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4405-4410.	7.1	170
61	Pharmacology of human trace amine-associated receptors: Therapeutic opportunities and challenges. , 2017, 180, 161-180.		159
62	The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. British Journal of Pharmacology, 2015, 172, 5979-6023.	5.4	158
63	Preferential role of D3 dopamine autoreceptor in regulation of dopamine release but not synthesis in nucleus accumbens and dorsal striatum of freely moving rats. Behavioural Pharmacology, 1995, 6, 74.	1.7	157
64	Trace Amine-Associated Receptor 1 Partial Agonism Reveals Novel Paradigm for Neuropsychiatric Therapeutics. Biological Psychiatry, 2012, 72, 934-942.	1.3	155
65	Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 11047-11054.	7.1	153
66	Following the trace of elusive amines. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 9474-9475.	7.1	152
67	Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D3 receptors. Neuroscience, 2002, 112, 39-49.	2.3	152
68	Rapid Conversion of Fibroblasts into Functional Forebrain GABAergic Interneurons by Direct Genetic Reprogramming. Cell Stem Cell, 2015, 17, 719-734.	11.1	152
69	Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice. Journal of Neurochemistry, 1998, 70, 1973-1978.	3.9	148
70	Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats. Journal of Neuroscience, 2018, 38, 1959-1972.	3.6	148
71	Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11035-11040.	7.1	135
72	Pharmacological Characterization of Membrane-Expressed Human Trace Amine-Associated Receptor 1 (TAAR1) by a Bioluminescence Resonance Energy Transfer cAMP Biosensor. Molecular Pharmacology, 2008, 74, 585-594.	2.3	135

#	Article	IF	Citations
73	Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: Role of D2 dopamine autoreceptors. Neuropharmacology, 2014, 81, 283-291.	4.1	133
74	The Concise Guide to PHARMACOLOGY 2015/16: Ligandâ€gated ion channels. British Journal of Pharmacology, 2015, 172, 5870-5903.	5.4	133
75	Monoamine transporter pharmacology and mutant mice. Trends in Pharmacological Sciences, 2002, 23, 367-373.	8.7	122
76	Dopamine-Independent Locomotor Actions of Amphetamines in a Novel Acute Mouse Model of Parkinson Disease. PLoS Biology, 2005, 3, e271.	5.6	122
77	Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Frontiers in Molecular Neuroscience, 2011, 4, 38.	2.9	120
78	Viral infiltration of pancreatic islets in patients with COVID-19. Nature Communications, 2021, 12, 3534.	12.8	120
79	The Selective Serotonin-2A Receptor Antagonist M100907 Reverses Behavioral Deficits in Dopamine Transporter Knockout Mice. Neuropsychopharmacology, 2004, 29, 221-228.	5.4	119
80	The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. British Journal of Pharmacology, 2015, 172, 5956-5978.	5.4	119
81	Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiology of Disease, 2015, 74, 66-75.	4.4	119
82	Psychedelic Drugs in Biomedicine. Trends in Pharmacological Sciences, 2017, 38, 992-1005.	8.7	113
83	Potentiated Opioid Analgesia in Norepinephrine Transporter Knock-Out Mice. Journal of Neuroscience, 2000, 20, 9040-9045.	3.6	106
84	Remote control of induced dopaminergic neurons in parkinsonian rats. Journal of Clinical Investigation, 2014, 124, 3215-3229.	8.2	104
85	G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacological Research, 2016, 111, 1-16.	7.1	100
86	TAAR1 Modulates Cortical Glutamate NMDA Receptor Function. Neuropsychopharmacology, 2015, 40, 2217-2227.	5.4	98
87	Paradoxical Striatal Cellular Signaling Responses to Psychostimulants in Hyperactive Mice. Journal of Biological Chemistry, 2006, 281, 32072-32080.	3.4	97
88	Dissociation of rewarding and dopamine transporter-mediated properties of amphetamine. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7781-7786.	7.1	95
89	Trace Amine-Associated Receptors as Emerging Therapeutic Targets: TABLE 1. Molecular Pharmacology, 2009, 76, 229-235.	2.3	95
90	Rod Vision Is Controlled by Dopamine-Dependent Sensitization of Rod Bipolar Cells by GABA. Neuron, 2011, 72, 101-110.	8.1	93

#	Article	IF	Citations
91	Targeting Î²-arrestin2 in the treatment of <scp>l</scp> -DOPAâ€“induced dyskinesia in Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2517-26.	7.1	91
92	Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast-scan cyclic voltammetry. Neuroscience Letters, 2000, 281, 9-12.	2.1	90
93	The Electroretinogram as a Biomarker of Central Dopamine and Serotonin: Potential Relevance to Psychiatric Disorders. Biological Psychiatry, 2014, 75, 479-486.	1.3	89
94	Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. Neuropharmacology, 2015, 93, 308-313.	4.1	88
95	BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Frontiers in Endocrinology, 2012, 3, 105.	3.5	87
96	Hyperdopaminergia and NMDA Receptor Hypofunction Disrupt Neural Phase Signaling. Journal of Neuroscience, 2009, 29, 8215-8224.	3.6	86
97	Rapid Generation of Functional Dopaminergic Neurons From Human Induced Pluripotent Stem Cells Through a Single-Step Procedure Using Cell Lineage Transcription Factors. Stem Cells Translational Medicine, 2013, 2, 473-479.	3.3	81
98	G Protein-coupled Receptor Kinase Regulates Dopamine D3 Receptor Signaling by Modulating the Stability of a Receptor-Filamin-Î²-Arrestin Complex. Journal of Biological Chemistry, 2005, 280, 12774-12780.	3.4	80
99	Elimination of the Vesicular Acetylcholine Transporter in the Striatum Reveals Regulation of Behaviour by Cholinergic-Glutamatergic Co-Transmission. PLoS Biology, 2011, 9, e1001194.	5.6	80
100	Quantitation of in vivo measurements with carbon fiber microelectrodes. Journal of Neuroscience Methods, 2000, 95, 95-102.	2.5	78
101	Experimental Genetic Approaches to Addiction. Neuron, 2002, 36, 213-228.	8.1	78
102	Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 221-230.	11.4	78
103	Mice lacking the dopamine transporter display altered regulation of distal colonic motility. American Journal of Physiology - Renal Physiology, 2000, 279, G311-G318.	3.4	77
104	Behavioral Phenotyping of Dopamine Transporter Knockout Rats: Compulsive Traits, Motor Stereotypies, and Anhedonia. Frontiers in Psychiatry, 2018, 9, 43.	2.6	77
105	The Dopamine Metabolite 3-Methoxytyramine Is a Neuromodulator. PLoS ONE, 2010, 5, e13452.	2.5	76
106	Activation of the Trace Amine-Associated Receptor 1 Prevents Relapse to Cocaine Seeking. Neuropsychopharmacology, 2014, 39, 2299-2308.	5.4	75
107	Genetics of Childhood Disorders: XXIV. ADHD, Part 8: Hyperdopaminergic Mice as an Animal Model of ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 380-382.	0.5	74
108	Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. Journal of Neurochemistry, 2004, 91, 362-373.	3.9	74

#	Article	IF	Citations
109	Functional polymorphisms of the brain serotonin synthesizing enzyme tryptophan hydroxylase-2. Cellular and Molecular Life Sciences, 2006, 63, 6-11.	5.4	73
110	In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. European Journal of Pharmacology, 1996, 308, 261-269.	3.5	72
111	Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene. Biological Psychiatry, 1999, 46, 1124-1130.	1.3	72
112	An animal model of attention deficit hyperactivity disorder. Trends in Molecular Medicine, 2000, 6, 43-44.	2.6	72
113	Local Knockdown of Genes in the Brain Using Small Interfering RNA: A Phenotypic Comparison with Knockout Animals. Biological Psychiatry, 2007, 61, 65-69.	1.3	72
114	Gene-dose dependent effects of methamphetamine on interval timing in dopamine-transporter knockout mice. Neuropharmacology, 2012, 62, 1221-1229.	4.1	70
115	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Molecular Psychiatry, 2020, 25, 1611-1617.	7.9	70
116	Hyperdopaminergic Tone Erodes Prefrontal Long-Term Potential via a D₂Receptor-Operated Protein Phosphatase Gate. Journal of Neuroscience, 2009, 29, 14086-14099.	3.6	68
117	Dopamine transporter mutant mice in experimental neuropharmacology. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377, 301-313.	3.0	67
118	Understanding autism and other neurodevelopmental disorders through experimental translational neurobehavioral models. Neuroscience and Biobehavioral Reviews, 2016, 65, 292-312.	6.1	63
119	Transgenic mouse models for ADHD. Cell and Tissue Research, 2013, 354, 259-271.	2.9	62
120	Dopamine transporter mutant animals: a translational perspective. Journal of Neurogenetics, 2016, 30, 5-15.	1.4	61
121	Human Accelerated Regions and Other Human-Specific Sequence Variations in the Context of Evolution and Their Relevance for Brain Development. Genome Biology and Evolution, 2018, 10, 166-188.	2.5	61
122	Molecular Biology, Pharmacology and Functional Role of the Plasma Membrane Dopamine Transporter. CNS and Neurological Disorders - Drug Targets, 2006, 5, 45-56.	1.4	60
123	Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Molecular Psychiatry, 2022, 27, 34-37.	7.9	59
124	The trace amine-associated receptor 1 modulates methamphetamine's neurochemical and behavioral effects. Frontiers in Neuroscience, 2015, 9, 39.	2.8	57
125	Cross-hemispheric dopamine projections have functional significance. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6985-6990.	7.1	55
126	Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB Journal, 2006, 20, 2541-2543.	0.5	53

#	Article	IF	Citations
127	Reduced expression of the vesicular acetylcholine transporter causes learning deficits in mice. Genes, Brain and Behavior, 2009, 8, 23-35.	2.2	53
128	Exogenous Â-Synuclein Decreases Raft Partitioning of Cav2.2 Channels Inducing Dopamine Release. Journal of Neuroscience, 2014, 34, 10603-10615.	3.6	53
129	Insights into the Structure and Pharmacology of the Human Trace Amineâ€Associated Receptor 1 (hTAAR1): Homology Modelling and Docking Studies. Chemical Biology and Drug Design, 2013, 81, 509-516.	3.2	52
130	In Vivo Amphetamine Action is Contingent on Î±CaMKII. Neuropsychopharmacology, 2014, 39, 2681-2693.	5.4	51
131	Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases. Expert Opinion on Therapeutic Targets, 2018, 22, 513-526.	3.4	50
132	Tryptophan hydroxylase 2 genotype determines brain serotonin synthesis but not tissue content in C57Bl/6 and BALB/c congenic mice. Neuroscience Letters, 2010, 481, 6-11.	2.1	49
133	Optogenetically-induced tonic dopamine release from VTA-nucleus accumbens projections inhibits reward consummatory behaviors. Neuroscience, 2016, 333, 54-64.	2.3	48
134	D₁Dopamine Receptor Coupling to PLCÎ² Regulates Forward Locomotion in Mice. Journal of Neuroscience, 2013, 33, 18125-18133.	3.6	46
135	Trace Amine-Associated Receptor 5 Provides Olfactory Input Into Limbic Brain Areas and Modulates Emotional Behaviors and Serotonin Transmission. Frontiers in Molecular Neuroscience, 2020, 13, 18.	2.9	45
136	Trace amine associated receptor 1 and movement control. Parkinsonism and Related Disorders, 2008, 14, S99-S102.	2.2	44
137	MDMA ?ecstasy? alters hyperactive and perseverative behaviors in dopamine transporter knockout mice. Psychopharmacology, 2004, 173, 310-317.	3.1	43
138	Genetic and environmental modulation of neurodevelopmental disorders: Translational insights from labs to beds. Brain Research Bulletin, 2016, 125, 79-91.	3.0	43
139	Genetic NMDA Receptor Deficiency Disrupts Acute and Chronic Effects of Cocaine but not Amphetamine. Neuropsychopharmacology, 2008, 33, 2701-2714.	5.4	42
140	Design, Synthesis, and Evaluation of Thyronamine Analogues as Novel Potent Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists. Journal of Medicinal Chemistry, 2015, 58, 5096-5107.	6.4	42
141	Further Insights Into the Pharmacology of the Human Trace Amineâ€Associated Receptors: Discovery of Novel Ligands for <scp>TAAR</scp>1 by a Virtual Screening Approach. Chemical Biology and Drug Design, 2014, 84, 712-720.	3.2	41
142	Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. European Journal of Pharmacology, 1999, 370, 125-131.	3.5	40
143	Dopamine levels modulate the updating of tastant values. Genes, Brain and Behavior, 2007, 6, 314-320.	2.2	40
144	The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. British Journal of Pharmacology, 2015, 172, 5942-5955.	5.4	40

#	Article	IF	Citations
145	Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. American Journal of Physiology - Renal Physiology, 2011, 300, G303-G315.	3.4	39
146	Chronic SSRI Treatment Exacerbates Serotonin Deficiency in Humanized Tph2 Mutant Mice. ACS Chemical Neuroscience, 2013, 4, 84-88.	3.5	39
147	Noradrenergic Control of Cortico-Striato-Thalamic and Mesolimbic Cross-Structural Synchrony. Journal of Neuroscience, 2010, 30, 6387-6397.	3.6	38
148	Novel biguanide-based derivatives scouted as TAAR1 agonists: Synthesis, biological evaluation, ADME prediction and molecular docking studies. European Journal of Medicinal Chemistry, 2017, 127, 781-792.	5.5	38
149	The Effects of Chronic Amitriptyline on Zebrafish Behavior and Monoamine Neurochemistry. Neurochemical Research, 2018, 43, 1191-1199.	3.3	38
150	Behavioral characterization of DAT-KO rats and evidence of asocial-like phenotypes in DAT-HET rats: The potential involvement of norepinephrine system. Behavioural Brain Research, 2019, 359, 516-527.	2.2	38
151	Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy. Science Translational Medicine, 2016, 8, 370ra181.	12.4	37
152	Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. Cellular Signalling, 2009, 21, 87-94.	3.6	36
153	Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug and Alcohol Dependence, 2009, 104, 187-196.	3.2	36
154	Effects of acute and chronic arecoline in adult zebrafish: Anxiolytic-like activity, elevated brain monoamines and the potential role of microglia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 104, 109977.	4.8	36
155	Dopamine D2 and D3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats. European Journal of Pharmacology, 1994, 261, 327-331.	3.5	35
156	Dopamine turnover in the mediobasal hypothalamus in rat fetuses. Neuroscience, 1999, 89, 235-241.	2.3	35
157	G Protein-Coupled Receptor Kinase/Î²-Arrestin Systems and Drugs of Abuse: Psychostimulant and Opiate Studies in Knockout Mice. NeuroMolecular Medicine, 2004, 5, 041-050.	3.4	35
158	TAAR1-dependent effects of apomorphine in mice. International Journal of Neuropsychopharmacology, 2014, 17, 1683-1693.	2.1	35
159	Characterization of conditioned place preference to cocaine in congenic dopamine transporter knockout female mice. Psychopharmacology, 2005, 180, 408-413.	3.1	34
160	Presynaptic dopaminergic function is largely unaltered in mesolimbic and mesostriatal terminals of adult rats that were prenatally exposed to cocaine. Brain Research, 2003, 961, 63-72.	2.2	33
161	Increased context-dependent conditioning to amphetamine in mice lacking TAAR1. Pharmacological Research, 2016, 103, 206-214.	7.1	33
162	A Regulatory Domain in the N Terminus of Tryptophan Hydroxylase 2 Controls Enzyme Expression. Journal of Biological Chemistry, 2008, 283, 13216-13224.	3.4	32

#	Article	IF	Citations
163	Long-term optical stimulation of channelrhodopsin-expressing neurons to study network plasticity. Frontiers in Molecular Neuroscience, 2013, 6, 22.	2.9	32
164	In-vivo pharmacology of Trace-Amine Associated Receptor 1. European Journal of Pharmacology, 2015, 763, 136-142.	3.5	32
165	Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy. Expert Opinion on Therapeutic Targets, 2018, 22, 319-330.	3.4	32
166	Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON l-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain, 2008, 131, 3361-3379.	7.6	30
167	A homology modelling-driven study leading to the discovery of the first mouse trace amine-associated receptor 5 (TAAR5) antagonists. MedChemComm, 2016, 7, 353-364.	3.4	30
168	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Molecular Neurobiology, 2018, 55, 1054-1067.	4.0	30
169	Altered Sexual Behavior in Dopamine Transporter (DAT) Knockout Male Rats: A Behavioral, Neurochemical and Intracerebral Microdialysis Study. Frontiers in Behavioral Neuroscience, 2020, 14, 58.	2.0	30
170	Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. European Journal of Medicinal Chemistry, 2018, 146, 171-184.	5.5	28
171	Increased dopamine transmission and adult neurogenesis in trace amine-associated receptor 5 (TAAR5) knockout mice. Neuropharmacology, 2021, 182, 108373.	4.1	28
172	Application of microdialysis and voltammetry to assess dopamine functions in genetically altered. Psychopharmacology, 1999, 147, 30-32.	3.1	27
173	Noveltyâ€related behavior of young and adult dopamine transporter knockout rats: Implication for cognitive and emotional phenotypic patterns. Genes, Brain and Behavior, 2018, 17, e12463.	2.2	27
174	Trace Amine-Associated Receptor 1 Modulates the Locomotor and Sensitization Effects of Nicotine. Frontiers in Pharmacology, 2018, 9, 329.	3.5	27
175	Microdialysis Studies on the Action of Tolcapone on Pharmacologicallyâ€Elevated Extracellular Dopamine Levels in Conscious Rats. Basic and Clinical Pharmacology and Toxicology, 1999, 85, 233-238.	0.0	26
176	Response to Zhang et al., (2005) Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron 45, 11â€“16. Neuron, 2005, 48, 702-703.	8.1	26
177	Regulation of dopamine release and metabolism in rat striatum in vivo: Effects of dopamine receptor antagonists. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1995, 19, 1285-1303.	4.8	25
178	Reply: receptor specificity of G-protein-coupled receptor kinases. Trends in Pharmacological Sciences, 2000, 21, 366-367.	8.7	25
179	The Dopamine Transporter Expression Level Differentially Affects Responses to Cocaine and Amphetamine. Journal of Neurogenetics, 2014, 28, 112-121.	1.4	25
180	The zebrafish tail immobilization (ZTI) test as a new tool to assess stress-related behavior and a potential screen for drugs affecting despair-like states. Journal of Neuroscience Methods, 2020, 337, 108637.	2.5	25

#	Article	IF	Citations
181	CRISPR/Cas9 Technology in Translational Biomedicine. Cellular Physiology and Biochemistry, 2020, 54, 354-370.	1.6	25
182	Understanding complex dynamics of behavioral, neurochemical and transcriptomic changes induced by prolonged chronic unpredictable stress in zebrafish. Scientific Reports, 2020, 10, 19981.	3.3	24
183	Sonoluminescence of aqueous solutions of lanthanide salts. Russian Chemical Bulletin, 2003, 52, 1969-1973.	1.5	23
184	Strengths and limitations of genetic models of ADHD. ADHD Attention Deficit and Hyperactivity Disorders, 2010, 2, 21-30.	1.7	22
185	The role of GRK6 in animal models of Parkinson's Disease and L-DOPA treatment. Scientific Reports, 2012, 2, 301.	3.3	22
186	Deficit in working memory and abnormal behavioral tactics in dopamine transporter knockout rats during training in the 8-arm maze. Behavioural Brain Research, 2020, 390, 112642.	2.2	22
187	DDD mice, a novel acute mouse model of Parkinsonâ€™s disease. Neurology, 2006, 67, S12-7.	1.1	22
188	A functional alternative splicing mutation in human tryptophan hydroxylase-2. Molecular Psychiatry, 2011, 16, 1169-1176.	7.9	21
189	Dopamine D2 Receptor Relies upon PPM/PP2C Protein Phosphatases to Dephosphorylate Huntingtin Protein. Journal of Biological Chemistry, 2014, 289, 11715-11724.	3.4	21
190	Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397. Frontiers in Pharmacology, 2018, 9, 645.	3.5	21
191	Intracerebroventricular injection of ouabain causes mania-like behavior in mice through D2 receptor activation. Scientific Reports, 2019, 9, 15627.	3.3	21
192	Delineating muscarinic receptor functions. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12222-12223.	7.1	20
193	Response to Correspondence: Loss-of-Function Mutation in Tryptophan Hydroxylase-2 Identified in Unipolar Major Depression. Neuron, 2005, 48, 705-706.	8.1	20
194	Novel 1-Amidino-4-Phenylpiperazines as Potent Agonists at Human TAAR1 Receptor: Rational Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Pharmaceuticals, 2020, 13, 391.	3.8	20
195	Selective Deletion of GRK2 Alters Psychostimulant-Induced Behaviors and Dopamine Neurotransmission. Neuropsychopharmacology, 2014, 39, 2450-2462.	5.4	19
196	Hit-to-Lead Optimization of Mouse Trace Amine Associated Receptor 1 (mTAAR1) Agonists with a Diphenylmethane-Scaffold: Design, Synthesis, and Biological Study. Journal of Medicinal Chemistry, 2016, 59, 9825-9836.	6.4	19
197	Persistent Hyperdopaminergia Decreases the Peak Frequency of Hippocampal Theta Oscillations during Quiet Waking and REM Sleep. PLoS ONE, 2009, 4, e5238.	2.5	19
198	Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinsonâ€™s Disease and L-DOPA Treatment. CNS and Neurological Disorders - Drug Targets, 2012, 11, 251-263.	1.4	19

#	Article	IF	Citations
199	Identification of TAAR5 Agonist Activity of Alpha-NETA and Its Effect on Mismatch Negativity Amplitude in Awake Rats. Neurotoxicity Research, 2018, 34, 442-451.	2.7	18
200	BRET Approaches to Characterize Dopamine and TAAR1 Receptor Pharmacology and Signaling. Methods in Molecular Biology, 2013, 964, 107-122.	0.9	17
201	Recombinant Adeno-Associated Virus-mediated rescue of function in a mouse model of Dopamine Transporter Deficiency Syndrome. Scientific Reports, 2017, 7, 46280.	3.3	16
202	Effects of intrastriatal infusion of d2 and d3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study). Pharmacological Research, 2001, 43, 283-290.	7.1	15
203	Sustained Nâ€methylâ€<scp>d</scp>â€aspartate receptor hypofunction remodels the dopamine system and impairs phasic signaling. European Journal of Neuroscience, 2014, 40, 2255-2263.	2.6	15
204	Trace Amine-Associated Receptor 1 Agonist Modulates Mismatch Negativity-Like Responses in Mice. Frontiers in Pharmacology, 2019, 10, 470.	3.5	15
205	Comparative analysis of the influence of a high-fat/high-carbohydrate diet on the level of anxiety and neuromotor and cognitive functions in Wistar and DAT-KO rats. Physiological Reports, 2019, 7, e13987.	1.7	15
206	Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders. Heliyon, 2020, 6, e03990.	3.2	15
207	TAAR5 receptor agonist affects sensory gating in rats. Neuroscience Letters, 2018, 666, 144-147.	2.1	14
208	Dopamine D₂ Receptor Supersensitivity as a Spectrum of Neurotoxicity and Status in Psychiatric Disorders. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 519-526.	2.5	14
209	Rats Lacking Dopamine Transporter Display Increased Vulnerability and Aberrant Autonomic Response to Acute Stress. Biomolecules, 2020, 10, 842.	4.0	14
210	Effects of a psychostimulant drug Sydnocarb on rat brain dopaminergic transmission in vivo. European Journal of Pharmacology, 1997, 340, 53-58.	3.5	13
211	Dopaminergic transmission in the rat striatum in vivo in conditions of pharmacological modulation. Neuroscience and Behavioral Physiology, 2002, 32, 183-188.	0.4	13
212	Putative Trace-AmineÂAssociated Receptor 5 (TAAR5) Agonist Î±-NETA Increases Electrocorticogram Gamma-Rhythm in Freely Moving Rats. Cellular and Molecular Neurobiology, 2020, 40, 203-213.	3.3	13
213	Novel translational rat models of dopamine transporter deficiency. Neural Regeneration Research, 2018, 13, 2091.	3.0	13
214	Trace Amine-Associated Receptor 2 Is Expressed in the Limbic Brain Areas and Is Involved in Dopamine Regulation and Adult Neurogenesis. Frontiers in Behavioral Neuroscience, 2022, 16, 847410.	2.0	13
215	Mesolimbic dopamine in obesity and diabetes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R601-R602.	1.8	12
216	Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. European Journal of Pharmacology, 2018, 829, 129-140.	3.5	12

#	Article	IF	Citations
217	Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats. Neuropharmacology, 2019, 144, 184-192.	4.1	12
218	Remoxipride and raclopride differ from metoclopramide by their effects on striatal dopamine release and biosynthesis in rats. Neuropharmacology, 1994, 33, 215-219.	4.1	11
219	A Caenorhabditis elegans model to study dopamine transporter deficiency syndrome. European Journal of Neuroscience, 2017, 45, 207-214.	2.6	11
220	Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium. Molecular Psychiatry, 2019, 24, 1099-1111.	7.9	11
221	Effect of trace amine-associated receptor 1 agonist RO5263397 on sensory gating in mice. NeuroReport, 2019, 30, 1004-1007.	1.2	10
222	The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats. Cellular and Molecular Neurobiology, 2020, 40, 215-228.	3.3	10
223	Early Adolescence Prefrontal Cortex Alterations in Female Rats Lacking Dopamine Transporter. Biomedicines, 2021, 9, 157.	3.2	10
224	Pattern of TAAR5 Expression in the Human Brain Based on Transcriptome Datasets Analysis. International Journal of Molecular Sciences, 2021, 22, 8802.	4.1	10
225	Applying a Fast-Scan Cyclic Voltammetry to Explore Dopamine Dynamics in Animal Models of Neuropsychiatric Disorders. Cells, 2022, 11, 1533.	4.1	10
226	Dopamine Transporter and Vesicular Monoamine Transporter Knockout Mice: Implications for Parkinson's Disease. , 2001, 62, 179-190.		9
227	Sonoluminescence of aqueous solutions of sulfuric acid and sulfur dioxide. Russian Chemical Bulletin, 2003, 52, 1966-1968.	1.5	9
228	Real-Time Accumbal Dopamine Response to Negative Stimuli: Effects of Ethanol. ACS Chemical Neuroscience, 2019, 10, 1986-1991.	3.5	9
229	Stereoisomers of the atypical neuroleptic carbidine modulate striatal dopamine release in awake rats. Neuropharmacology, 1991, 30, 1251-1254.	4.1	8
230	Substances increasing the extracellular content of dopamine in the striatum prevent the development of haloperidol catalepsy in rats. Bulletin of Experimental Biology and Medicine, 1996, 121, 399-401.	0.8	8
231	No effect of C1473G polymorphism in the tryptophan hydroxylase 2 gene on the response of the brain serotonin system to chronic fluoxetine treatment in mice. Neuroscience Letters, 2017, 653, 264-268.	2.1	8
232	Behavioral Effects of a Potential Novel TAAR1 Antagonist. Frontiers in Pharmacology, 2018, 9, 953.	3.5	8
233	In vivo voltammetric evidence that locus coeruleus activation predominantly releases norepinephrine in the infralimbic cortex: Effect of acute ethanol. Synapse, 2019, 73, e22080.	1.2	8
234	A New Paradigm for Training Hyperactive Dopamine Transporter Knockout Rats: Influence of Novel Stimuli on Object Recognition. Frontiers in Behavioral Neuroscience, 2021, 15, 654469.	2.0	8

#	Article	IF	Citations
235	Divergent Dimethylarginine Dimethylaminohydrolase Isoenzyme Expression in the Central Nervous System. Cellular and Molecular Neurobiology, 2022, 42, 2273-2288.	3.3	8
236	Dopamine receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
237	Estimation of the interstitial free concentration of the putative dopamine D3 receptor selective agonist 7-OH-DPAT in the dorsal striatum of freely moving rats. Neuroscience Letters, 1995, 193, 65-67.	2.1	7
238	The after-hours circadian mutant has reduced phenotypic plasticity in behaviors at multiple timescales and in sleep homeostasis. Scientific Reports, 2017, 7, 17765.	3.3	7
239	Effect of alpha-NETA on auditory event related potentials in sensory gating study paradigm in mice. Neuroscience Letters, 2019, 712, 134470.	2.1	7
240	Minimal Age-Related Alterations in Behavioral and Hematological Parameters in Trace Amine-Associated Receptor 1 (TAAR1) Knockout Mice. Cellular and Molecular Neurobiology, 2020, 40, 273-282.	3.3	7
241	Genetic Deletion of Trace-Amine Associated Receptor 9 (TAAR9) in Rats Leads to Decreased Blood Cholesterol Levels. International Journal of Molecular Sciences, 2021, 22, 2942.	4.1	7
242	Trace amine-associated receptors at the cross-road between innate olfaction of amines, emotions, and adult neurogenesis. Neural Regeneration Research, 2022, 17, 1257.	3.0	7
243	Linking Ethanol-Addictive Behaviors With Brain Catecholamines: Release Pattern Matters. Frontiers in Behavioral Neuroscience, 2021, 15, 795030.	2.0	7
244	Effect of argon on the multibubble sonoluminescence of cerium, terbium, and dysprosium trichlorides. Russian Chemical Bulletin, 2008, 57, 1831-1836.	1.5	6
245	Neuronal Functions and Emerging Pharmacology of TAAR1. Topics in Medicinal Chemistry, 2014, , 175-194.	0.8	6
246	Rare cis-configured 2,4-disubstituted 1-alkylpiperidines: synthesized and tested against trace-amine-associated receptor 1 (TAAR1). Mendeleev Communications, 2021, 31, 488-489.	1.6	6
247	Modulation of Spatial Memory Deficit and Hyperactivity in Dopamine Transporter Knockout Rats via Î±2A-Adrenoceptors. Frontiers in Psychiatry, 2022, 13, 851296.	2.6	6
248	Search for Structural Basis of Interactions of Biogenic Amines with Human TAAR1 and TAAR6 Receptors. International Journal of Molecular Sciences, 2022, 23, 209.	4.1	6
249	Expression of Trace Amine-Associated Receptors in the Murine and Human Hippocampus Based on Public Transcriptomic Data. Cells, 2022, 11, 1813.	4.1	6
250	Effect of bromantane, a new immunostimulating agent with psychostimulating activity, on the release and metabolism of dopamine in the striatum of freely moving rats. A microdialysis study. Bulletin of Experimental Biology and Medicine, 1995, 119, 294-296.	0.8	5
251	Simultaneous monitoring of dopamine, its metabolites and trans-isomer of atypical neuroleptic drug carbidine concentrations in striatal dialysates of conscious rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 291-305.	4.8	5
252	Anomalous isotopic effect in multibubble sonoluminescence of aqueous solutions of terbium chloride. JETP Letters, 2006, 83, 493-496.	1.4	5

#	Article	IF	Citations
253	Reply to Belmaker et al. : GSK3Î² haploinsufficiency results in lithium-like effects in the forced-swim test. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, .	7.1	5
254	The TAAR5 agonist Î±-NETA causes dyskinesia in mice. Neuroscience Letters, 2019, 704, 208-211.	2.1	5
255	Enhanced Dopamine Transmission and Hyperactivity in the Dopamine Transporter Heterozygous Mice Lacking the D3 Dopamine Receptor. International Journal of Molecular Sciences, 2020, 21, 8216.	4.1	5
256	Minor Changes in Erythrocyte Osmotic Fragility in Trace Amine-Associated Receptor 5 (TAAR5) Knockout Mice. International Journal of Molecular Sciences, 2021, 22, 7307.	4.1	5
257	Disruption of the PDZ domainâ€“binding motif of the dopamine transporter uniquely alters nanoscale distribution, dopamine homeostasis, and reward motivation. Journal of Biological Chemistry, 2021, 297, 101361.	3.4	5
258	Discovery of Novel Trace Amine-Associated Receptor 5 (TAAR5) Antagonists Using a Deep Convolutional Neural Network. International Journal of Molecular Sciences, 2022, 23, 3127.	4.1	5
259	Trace Amine Associate Receptor 1 (TAAR1) as a New Target for the Treatment of Cognitive Dysfunction in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 7811.	4.1	5
260	Quenching of electronically excited Ln3+* ions by C60 fullerene. Russian Chemical Bulletin, 2006, 55, 955-960.	1.5	4
261	Sonoluminescence of terbium chloride in an H2O-D2O mixture. Russian Chemical Bulletin, 2006, 55, 1114-1118.	1.5	4
262	Multibubble sonoluminescence of europium(III) chloride in heavy water. Russian Chemical Bulletin, 2008, 57, 1827-1830.	1.5	4
263	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110134.	4.8	4
264	Microdialysis study of effects of atypical neuroleptics and anxiolytics on striatal dopamine release and metabolism in conscious rats. Bulletin of Experimental Biology and Medicine, 1991, 111, 655-658.	0.8	3
265	Effects of N-acetylaspartic acid on the brain after frontal lobectomy in rats: Antiamnestic effect and influence on monoamine content. Bulletin of Experimental Biology and Medicine, 1993, 115, 155-158.	0.8	3
266	3.2 Role of Dopamine Transporters in Neuronal Homeostasis. , 2009, , 88-99.		3
267	Deregulation of Trace Amine-Associated Receptors (TAAR) Expression and Signaling Mode in Melanoma. Biomolecules, 2022, 12, 114.	4.0	3
268	Evaluation of Approach to a Conspecific and Blood Biochemical Parameters in TAAR1 Knockout Mice. Brain Sciences, 2022, 12, 614.	2.3	3
269	Different effects of typical and atypical neuroleptics on K+-stimulated dopamine release from isolated rat striatum. Bulletin of Experimental Biology and Medicine, 1992, 114, 971-974.	0.8	2
270	Selective analyzers of D2-dopamine receptors modulate serotonin metabolism in the striatum and nucleus accumbens after dopaminergic neuron blockade. Bulletin of Experimental Biology and Medicine, 1992, 113, 821-824.	0.8	2

#	Article	IF	Citations
271	Age-related changes in the dopaminergic system of rat striatum. Bulletin of Experimental Biology and Medicine, 1993, 115, 331-333.	0.8	2
272	On the emitters of sulfuric acid sonoluminescence. Russian Chemical Bulletin, 2005, 54, 1793-1797.	1.5	2
273	Identification of a novel trace amine-associated receptor 1 agonist with in vivo activity. European Neuropsychopharmacology, 2019, 29, S190.	0.7	2
274	A low-cost and customizable alternative for commercial implantable cannula for intracerebral administration in mice. HardwareX, 2020, 8, e00120.	2.2	2
275	Ouabain-Induced Gene Expression Changes in Human iPSC-Derived Neuron Culture Expressing Dopamine and cAMP-Regulated Phosphoprotein 32 and GABA Receptors. Brain Sciences, 2021, 11, 203.	2.3	2
276	Ð¡Ð¾Ð²ÑÐµÐ¼ÐµÐ½Ð½Ð¾Ð¼Ñ ÑÐ¾ÑÑ,Ð¾ÑÐ½Ð¸Ðµ Ð¼Ð¾Ð»ÐµÐºÑƒÐ»ÑÑ€Ð½Ð¾-Ð³ÐµÐ½ÐµÑ‚Ð¸Ñ‡ÐµÑÐºÐ¾Ð¹ Ñ. Ð¸ÑÑÐ»Ð	2	
277	Effect of haloperidol on extracellular concentrations of dopamine and its metabolites in the rat septum during muricidal aggression. Bulletin of Experimental Biology and Medicine, 1992, 114, 1221-1223.	0.8	1
278	Use of sodium hydroxybutyrate and nooglutyl to correct dopamine release in the striatum of prenatally alcoholized rat pups. Bulletin of Experimental Biology and Medicine, 1993, 116, 832-834.	0.8	1
279	Effect of original psychostimulant drug sydnocarb on brain dopaminergic transmission. Behavioural Pharmacology, 1995, 6, 28.	1.7	1
280	D3 dopamine receptor and development of anxiety in rats. Behavioural Pharmacology, 1995, 6, 37.	1.7	1
281	Effect of subchronic administration of tolcapone on L-DOPA-and carbidopa-induced release of striatal dopamine and its metabolites. Bulletin of Experimental Biology and Medicine, 1998, 125, 145-147.	0.8	1
282	EDITORIAL: GENETIC MODELS IN PHARMACOLOGY: PRESENT STATUS AND FUTURE. Pharmacological Research, 1999, 39, 403-404.	7.1	1
283	Sonoluminescence of aqueous solution of gadolinium chloride. Russian Chemical Bulletin, 2005, 54, 1383-1386.	1.5	1
284	Dopamine: from pharmacology to molecular biology and back. Wiener Klinische Wochenschrift, 2006, 118, 565-568.	1.9	1
285	Food Reward in the Absence of Taste Receptor Signaling. Neuron, 2008, 58, 295.	8.1	1
286	Regulation of Dopamine-Dependent Behaviors by G Protein-Coupled Receptor Kinases. Methods in Pharmacology and Toxicology, 2016, , 237-269.	0.2	1
287	No tolerance to anticompulsive activity of trace amine-associated receptor 1 agonist following repeated administration. European Neuropsychopharmacology, 2018, 28, S38-S39.	0.7	1
288	Effects of dopamine level on object recognition and formation of cognitive maps in rats. European Neuropsychopharmacology, 2019, 29, S139-S140.	0.7	1

#	Article	IF	Citations
289	Novel medium-sized di(het)areno-fused 1,4,7-(oxa)thiadiazecines as probes for aminergic receptors. Mendeleev Communications, 2021, 31, 501-503.	1.6	1
290	Trace Amine-Associated Receptor 1 (TAAR1). , 2017, , 1-12.		1
291	Cell Replacement Therapy in Parkinsonâ€™s Diseaseâ€”History of Development and Prospects for Use in Clinical Practice. Molecular Biology, 2020, 54, 827-839.	1.3	1
292	Rare single nucleotide variants in COL5A1 promoter do not play a major role in keratoconus susceptibility associated with rs1536482. BMC Ophthalmology, 2021, 21, 357.	1.4	1
293	A General Approach to Spirocyclic Piperidines via Castagnoliâ€“Cushman Chemistry. Synthesis, 0, , .	2.3	1
294	Action of small doses of irradiation on hypothalamic monoamine levels in hypoxic and normoxic rats. Bulletin of Experimental Biology and Medicine, 1991, 112, 1508-1510.	0.8	0
295	Comparison of neurochemical activity profiles of remoxipride, raclopride, and metoclopramide. Bulletin of Experimental Biology and Medicine, 1992, 114, 1135-1139.	0.8	0
296	Dopamine autoreceptors of subtype D3 regulate mainly dopamine release in the basal ganglia of rat brain. Bulletin of Experimental Biology and Medicine, 1996, 121, 392-396.	0.8	0
297	Effect of the aspartic acid derivatives N-acetyl-aspartate and its phosphonic analog PIR-87-6-0 on the release of dopamine from rat striatum duringin vitro perfusion. Bulletin of Experimental Biology and Medicine, 1997, 123, 49-51.	0.8	0
298	S.28.02 Influence of variants of TPH2 on the regulation of the central serotonin system. European Neuropsychopharmacology, 2006, 16, S203-S204.	0.7	0
299	Chapter 5.1 Microdialysis in genetically altered animals. Handbook of Behavioral Neuroscience, 2006, , 399-417.	0.7	0
300	Attention-deficit hyperactivity disorder. , 0, , 164-172.		0
301	Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 447-462.	0.7	0
302	Differences in effects of NMDA receptor antagonists in BARR2-KO mice. European Neuropsychopharmacology, 2016, 26, S276.	0.7	0
303	Peripheral immunization of mice to produce antibodies against NMDA receptor as a potential approach to create a rodent model of schizophrenia. European Neuropsychopharmacology, 2016, 26, S271-S272.	0.7	0
304	P.112 Impaired conditioning in dopamine transporter knockout rats. European Neuropsychopharmacology, 2019, 29, S94-S95.	0.7	0
305	P.059 Identifying the role of trace amine-associated receptor 9 in behaviour, brain neurochemistry and blood biochemistry. European Neuropsychopharmacology, 2020, 40, S39-S40.	0.7	0
306	P.062 Dopamine reuptake deficiency does not affect motor long-term motor memory in dopamine transporter-knockout rats. European Neuropsychopharmacology, 2020, 40, S41.	0.7	0

#	Article	IF	Citations
307	Dopamine System. , 2020, , 1-7.		0
308	Trace Amine-Associated Receptors. , 2021, , 1-6.		0
309	Involvement of Dopamine Transporters in Psychiatric Disorders. Neurobiological Foundation of Aberrant Behaviors, 2000, , 1-18.	0.2	0
310	Genetically Altered Mice as Models for Understanding Brain Disorders. Research and Perspectives in Neurosciences, 2003, , 65-84.	0.4	0
311	Trace Amines and Their Receptors. , 2014, , 92-93.		0
312	Optogenetics: Applications in neurobiology. Biological Communications, 2017, 62, 261-271.	0.8	0
313	Trace Amine-Associated Receptor 1 (TAAR1). , 2018, , 5567-5577.		0
314	Dopamine System. , 2021, , 554-560.		0
315	Trace Amine-Associated Receptors. , 2021, , 1498-1504.		0